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ABSTRACT
ATTENUATION OF ANTAGONIST-INDUCED IMPAIRMENT 
IN DOPAMINE RECEPTOR ONTOGENY 
BY L-PROLYL-L-LEUCYL-GLYCINAMIDE 
by
Mohamad Iqbal Saleh, M.D.
It has been shown by others that the prenatal treatment 
of rats with haloperidol, a dopamine D2 receptor antagonist, 
leads to a permanent reduction in the number of striatal 
dopamine D2 receptors in adulthood. Conversely, postnatal 
treatment of lactating dams with haloperidol from birth for 
21 days, leads to an increase in the number of striatal 
dopamine D2 receptors in the litters, when assessed as 
adults. The present study was undertaken in order to 
determine whether chronic, long-term postnatal challenge of 
rat pups per se, with specific dopamine D1 and D2 receptor 
antagonists, would modify the ontogeny of the respective 
receptor types. Since the neuropeptide
L-prolyl-L-leucyl-glycinamide (PLG) attenuates the effect of 
haloperidol on dopamine D2 receptors in adult rats, it was of 
interest to determine whether PLG would modulate 
antagonist-induced alterations in the ontogeny of striatal 
dopamine D1 and D2 receptors. Half of the rats were treated 
daily for 32 cjlays from birth with SCH-23390 (0.30 mg/kg/d 
i.p.), a selective dopamine D1 antagonist; or spiroperidol 
(1.0 mg/kg/d i.p.), a selective dopamine D2 antagonist; or 
both SCH-23390 and spiroperidol; or saline. The other half 
of the litters were treated with PLG (1.0 mg/kg/d, i.p.), in 
combination with the other treatments. Animals were 
decapitated at 5,8, and 12 weeks from birth for neurochemical 
analysis of the striatum. Chronic SCH-23390 treatment 
produced a 70-80% decrease in the binding of [3H] SCH-23390 
(300 pM) to striatal homogenates. The alteration at 5 weeks 
was associated with a 78% decrease in the Bmax for [3H] 
SCH-23390 binding, and no change in the K^. Similarly, at 5, 
8, and 12 weeks, chronic spiroperidol treatment reduced the 
binding of [3H] spiroperidol (300pM) to striatal homogenates 
by 70-80%. The alteration at 5 weeks was associated with a 
74% decrease in the Bmax for [3H] spiroperidol binding, and 
no change in Kq . Furthermore, PLG attenuated these 
respective changes in dopamine D1 and D2 binding, when 
assessed at 5 and 8 weeks. These findings demonstrate that 
the postnatal period is a sensitive and critical time in the 
development of striatal dopamine Dl and D2 receptors and that 
PLG is able to attenuate the alterations in ontogeny that are 
produced by dopamine Dl and D2 receptor antagonists.
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Chapter I
Introduction
Anatomical Review:
Carlsson et al. (1958) made their important suggestion 
that dopamine is not only an intermediate precursor of 
norepinephrine synthesis, but is also a unique monoamine with 
specific properties-and functions in the central nervous 
system (CNS). Following this suggestion, Ahlstrtim and Fuxe 
(1964), using a histochemical formaldehyde condensation 
method, mapped the central monoaminergic systems in great 
detail. It was found that dopaminergic cell bodies are 
located mainly in three major areas:
1. Zona compacta of the substantia nigra (Ag)
2. Ventral tegmental area (A10)
3. Arcuate nucleus and the ventral periventricular 
hypothalamic nucleus (A12)
From the dopamine cells in Ag, the nigrostriatal 
dopamine system (dorsal component of the mesostriatal 
dopamine system) arises, and terminates in the caudate
I
nucleus, putamen, globus pallidus and subthalamic nucleus. 
From the dopamine cells in A^q , the mesolimbic dopamine 
system (ventral component of the mesostriatal dopamine 
system) arises, and terminates in the nucleus accumbens, 
olfactory tubercle, nucleus interstitialis stria terminalis, 
hypothalamus, preoptic area, prefrontal cortex, cingulate
cortex, hippocampus, amygdala, and midbrain; and from the 
dopamine cells in A12, the tuberoinfundibular and 
tuberohypophyseal dopamine system arises and terminates in 
the median eminence, infundibular stalk, and intermediate and 
neural lobes of the pituitary (Beckstead et al., 1979; and 
Nauta et al., 1978).
Proposed Function Of Dopamine Systems:
*
As of now, two major neurological functions can be 
directly related to dopamine systems:
1. Behavior: Various behaviors can be modulated by
dopaminergic transmission. The nigrostriatal pathway 
is associated with motor behavior, while the mesolimbic, 
mesocortical pathways are associated with mood behavior,
1.e., stereotyped behavior (Creese, 1973), self 
stimulation behavior (Phillips and Libiger, 1973), 
conditioned avoidance responding behavior (Ungerstedt, 
1971), stimulus control behavior (Ho and Huang, 1975), 
and feeding and drinking behavior (Ungerstedt, 1971).
2. Neuroendocrine function (tuberohypophyseal 
dopaminergic system): Neuroendocrine function was
recognized from studies on the effect of dopamine on the 
hypothalamus, gonadal steroids and prolactin secretion 
(MacLeod 1976).
Dopamine Receptors:
The properties of dopamine receptors were first 
characterized in 1975 following their identification by
receptor-binding techniques utilizing [3H]-butyrophenones,
the potent anti-psychotic drugs used in the treatment of
schizophrenia (Snyder et al., 1975; Seeman et al., 1975).
These receptors were termed dopamine D2 receptors, since
another type of dopamine receptor had been identified years
earlier, even though its functional properties were unknown
(Billard et al., 1974).
*
Later, Cools and Van Rossum (1976) modified the concept
of multiple dopamine receptors. Kebabian and Caine (1978)
followed up on that and classified dopamine receptors into Dj
and □2 receptors, where dopamine is the receptor that is
linked to dopamine-sensitive adenylate cyclase, and the
dopamine D2 receptor represents the group that is not linked
to dopamine sensitive adenylate cyclase. However, this
classification is not satisfactory since: 1— Adenylate
cyclase does not exist in all dopamine receptor- containing
tissue (i.e. pituitary) (Ahn et al., 1979). 2— It is not
practically possible to biochemically separate the amount of
dopamine receptors linked and nonlinked to adenylate cyclase 
*
(Kebabian and Caine, 1979). 3— There is no clear 
relationship between the effect of the dopamine agonists and 
antagonists on behavior and their effect on adenylate cyclase 
(Mcermed and Miller, 1979).
The gradual discovery of highly specific dopamine 
receptor agonists and antagonists made it possible to 
characterize dopamine D2 receptors (Creese et al., 1977;
Leysen et al., 1978, Laduron and Leysen, 1979) and dopamine 
Dj_ receptors (Iorio et al., 1981; Hyttel, 1983; Iorio et al., 
1983). Also, it was then possible to classify dopamine 
and 2 receptors on the basis of specific binding to selective 
agonists and antagonists.
Selective Dopamine Do and Studies:
Creese et al. (1977) and Laduron and Leysen (1979), 
using radioligand binding studies with [3H] spiroperidol, a 
selective dopamine D2 receptor antagonist, labeled dopamine 
d2 receptors in the central nervous system. Klemm et al. 
(1979) utilized autoradiography with [3H] spiroperidol and 
localized high densities of dopamine 2 receptors in the 
neostriatum (caudate-putamen), nucleus accumbens, olfactory 
tubercle, and also in the substantia nigra.
The dopamine receptors have been studied using
oxanthenes such as cis-[3H] piflupentixol (Hyttel, 1978) and
cis-(Z)-[3H] pifluthixol (Hyttel, 1981). However, these
radioligands also label dopamine D2 receptors (Hyttel and
Arnt, 1980). SCH-23390[(R)-(+)-7-Chloro-8-hydroxy-3-methyl- 
*
1-phenyl-2,3,4,5-tetrahydro-l-H-3-benzazepine] is a new 
benzazepine which is a selective antagonist (Iorio et al., 
1981; Hyttel, 1983) and shows a potent blockade of the 
dopamine-stimulated adenylate cyclase (Onali et al, 1984). 
Radioligand studies have shown that [3H]SCH-23390 labels and 
binds specifically and with high affinity to dopamine 
receptors in the neostriatum (Schulz et al., 1985).
Dopamine Receptor Distribution:
The distribution of dopamine and 2 receptors in the 
brain areas of different species was studied by Hyttel et al. 
(1978), It was found that there are 2-6 times more dopamine 
Di receptor binding sites than dopamine ^2 receptor binding 
sites in rat corpus striatum; the same ratio is found in the 
mouse striatum. In areas of the brain rich in dopamine 
receptors, the number of dopamine Di receptor binding sites 
is greater than the number of dopamine D2 receptor binding 
sites, but in different ratios (Hyttel, 1978; Hyttel and 
Arnt, 1986).
Today even though there have been intensive studies 
performed on the function of dopamine Di and ^2 receptors, 
there is still no clear picture of how dopamine Di and D2 
receptors and other neuroreceptors interact in the brain to 
carry out their function.
Dopamine Di, P2 Receptor Function And Interaction:
Marked correlation exists between the ability of 
neuroleptic drugs to displace [3H] spiroperidol from specific 
binding sites on dopamine D2 receptors and their 
anti-psychotic activity (Creese et al., 1979; Seeman, 1980). 
Therefore, the action of neuroleptics on dopamine D2 receptor 
sites can explain some the functions of dopamine receptor 
activation.
However, it seems that dopamine D2 receptors do not 
function independently of dopamine Di receptors, and several
studies have provided evidence for dopamine Di-D2 receptor
interaction. For example, SKF 38393, a dopamine receptor
agonist, stimulates the release of cAMP from superfused
striatal tissue slices; this stimulation is antagonized by LY
141865, a selective dopamine D2 receptor agonist.
Furthermore, (-)sulpiride, a dopamine D2 receptor antagonist,
prevents the effect of LY 141865 (Stool and Kebabian, 1981).
Low doses of spiroperidol can induce abnormal perioral
movements in rats; these abnormal movements can be
potentiated by SKF 38393, the dopamine agonist
(Rosengarten et al., 1983). It was also found that
intravenous administration of SKF 38393 and RU 24926, a
dopamine D2 agonist, produced synergestic effects on the
expression of stereotypic behavior and on the firing rate of
basal ganglia neurons in rats. Furthermore, simultaneous
stimulation of both dopamine and D2 receptors produces
greater firing rate and behavioral changes similar to those
produced by non-selective dopamine receptor agonists (i.e.
apomorphine; Walters et al., 1987). In vitro studies have 
*
also shown that haloperidol, at concentrations which appear 
to be selective for dopamine D2 receptor blockade, increases 
the release of [3H] acetylcholine (ACh) from superfused 
striatal tissue slices (Starke et al., 1983); SCH-23390, the 
dopamine antagonist, is capable of antagonizing [3H] ACh 
release. These findings suggest that dopamine and D2
receptor interaction may be an important determinant of
maintaining balanced behavioral activities.
6-Hvdroxvdopamine and Dopamine Receptors:
6-Hydroxydopamine, a relatively selective neurotoxin for
catecholaminergic neurons, produces destruction of central
noradrenergic and dopaminergic fibers after
intraeerebroventricular administration to rats (Kostrzewa and
*
Jacobowitz, 1974). To diminish noradrenergic fiber 
destruction, desmethylimpiramine (DMX), an inhibitor of 
norepinephrine reuptake, may be used as a pretreatment 
(Breese and Traylor, 1972). Also, by co-administering 
pargyline, a monoamine oxidase inhibitor, the destructive 
action of 6-hydroxydopamine on dopaminergic fibers can be 
potentiated (Breese and Traylor, 1970).
The destruction of dopamine nigrostriatal fibers is 
associated with specific motor behavioral dysfunctions, i.e., 
aphagia, adipsia and akinesia (Ungerstedt, 1971; Marshall et 
al,, 1974) and a proliferation of dopamine D2 receptors 
(Breese et al., 1984).
These alterations may appear in Parkinson's disease, 
where the number and function of dopamine cells is reduced in 
the substantia nigra. Also, after chronic anti-psychotic 
agents, such as haloperidol, the striatal dopamine receptors 
are greatly increased in number, and motor behavior 
dysfunctions are observed (Tarsy and Baldessarini, 1974).
Haloperidol and Dopamine Receptors:
Haloperidol is an anti-psychotic drug that is used 
chronically in man. Animal studies have shown that chronic 
injection of haloperidol causes up-regulation 
(supersensitivity) of striatal dopamine D2 receptors in adult 
rats (Muller and Seeman, 1977; Chiu et al,, 1981) and in 
neonatal rats (Rosengarten and Friedhoff, 1979).
Furthermore, haloperidol causes a down-regulation (decrease 
in number) of striatal dopamine D2 receptors in neonatal rats 
following prenatal administration (Rosengarten and Friedhoff, 
1979). However, haloperidol is a non-selective dopamine d2 
receptor antagonist (70% D2) (Murrin, 1982); new agents have 
been found which are more specific antagonists.
Dopamine and Dopamine Receptor Ontoaenvi 
A— Dopaminergic Input Prior to Birth
Three major dramatic changes in the dopaminergic input 
to rat striatum occur prior to birth and for the 8 week 
period after birth:
1) Tyrosine hydroxylase activity increases (Coyle et
i
al., 1976).
2) There is a gradual increase in dopamine 
concentration and dopamine uptake (Coyle et al., 1976). 
The rat striatum contains 12-24% of the adult (i.e., 90 
days old) level of dopamine at birth. The dopamine 
content increases slowly until it reaches adult levels 
by postnatal day 60, and then remains constant through
adulthood and senescence (up to 20 months of age).
3) There is a rapid increase in the dopamine receptor 
number up to adult levels by postnatal day 30-35 (Giorgi 
et al., 1987; Murrin, 1982).
B— Dopamine Receptor Ontogeny:
Giorgi et al. (1987) found that the density of dopamine
receptors labeled with [3H] SCH-23390 in rat striatum was
*
only 9% of the adult value at birth, and increased rapidly, 
continuing until day 35, when dopamine receptor density 
attained maximum values and then decreased significantly with 
age; i.e. the B ^ x  for dopamine D;l binding to the striatum at 
35 days was 1.75 pmol/mg protein versus 1.2 at 90 days, and 
0.89 at 270 days.
C— Dopamine_D2 Receptor Ontogeny:
Murrin (1982) studied the ontogeny of dopamine D2 
receptors using in vivo [3H] spiroperidol binding studies in 
5, 15 and 30 day old rat pups. It was found that dopamine D2 
receptors doubled in number between day 5 and day 15, and 
then gradually increased in number reaching adult levels by 
day 30. This observation is similar to the in vitro study on 
dopamine D2 receptor ontogeny by Pardo and Creese (1977). 
Impairment of Dopamine Receptor Ontogeny:
The normal ontogeny of dopamine D2 receptors can be 
impaired by prenatal treatment with dopamine receptor 
antagonists. Rosengarten and Friedhoff (1979) showed that 
when the neuroleptic haloperidol is administered to pregnant
10
dams, a persistent decrease in the number of dopamine D2
receptors occurs in the offspring. Later, it was found that
days 15-18 of the gestational period was the critical time
for that effect (Rosengarten et al., 1983). This finding was
confirmed by Miller and Friedhoff (1986).
It has also been shown that treatment of nursing dams
with haloperidol for 21 days after giving birth results in a
*
40% increase in the number of striatal dopamine D2 receptors 
in the littermates two weeks after the last dose of 
haloperidol has been administered to the dam (Rosengarten and 
Friedhoff, 1979). other studies have shown that treatment of 
neonatal rats with penfluridol, a neuroleptic similar to 
haloperidol, on alternate days during the first postnatal 
week does not affect the development of striatal dopamine D2 
receptors, although there is a supersensitive response of 
these rats to the dopamine receptor agonist, apomorphine, as 
adults (Coyle et al., 1981).
Until now, there have been no studies to determine the 
striatal dopamine and D2 receptor response to highly
4
selective dopamine and D2 antagonists administered either 
prenatally or postnatally. This type of specific experiment 
is important to gain more knowledge on the ontogeny of 
dopamine receptors and their response to chronic blockade by 
specific antagonists.
11
Dopamine Receptors Ana L-Prolvl-L-Leucvl-Glvcinaroide fPLGl:
It is accepted that the hypothalamic tissue of many
species, including man, contains a substance that inhibits
the release of melanocyte stimulating hormone (MSH) from the
pituitary gland (Kastin and Schally, 1966); this
neurohormonal substance is called melanocyte stimulating
hormone release inhibiting factor (MIF). Nair et al.(1971a)
determined the structure of MIF to be L-prolyl-L-leucyl-
glycinamide (PLG) and synthesized this substance, which had
biological activities similar to those of naturally-occurring
bovine MIF. It was also found that PLG has a short
biological half-life, approximately 9 minutes (Redding et
al., 1973). Several studies have demonstrated that PLG
produces a wide variety of behavioral and neurochemical
actions in the absence of the pituitary gland. The search
for a better and safer treatment for behavior dysfunctions
(i.e., psychoses and Parkinson's disease) has brought about
the promising role of PLG in specifically modulating
dopaminergic processes in the mammalian brain. It was found 
*
that PLG potentiates the effects of dihydroxyphenylalanine 
(L-dopa) on motor performance in both intact and 
hypophysectomized mice (Plotnikoff.1971) and in humans 
(Barbeau, 1975). PLG is also devoid of the adverse 
neurological side-effects of the L-dopa treatment (Barbeau et 
al., 1978). clinical studies indicated that PLG temporarily, 
but significantly, reduced the intensity of dyskinetic
12
symptoms associated with chronic anti-psychotic therapy 
(Ehrensing, 1974; Kastin et al., 1977).
Later, Chiu et al. (1981) showed that PLG was able to 
attenuate dopamine receptor supersensitivity caused by 
chronic administration of haloperidol in rats. Bhargava 
(1981a) also observed that PLG was able to inhibit the 
development of tolerance to the cataleptic and hypothermic 
effect of haloperidol in the rat. Chiu et al. (1981) also 
showed that PLG is able to block the behavioral 
supersensitivity of dopamine receptors induced by 
haloperidol.
Other studies have also demonstrated important findings. 
Bhargava (1981) found that PLG and its cyclic analog, cyclo 
(Leu-Gly), are able to block the development of analgesic 
tolerance and dopamine receptor supersensitivity induced by 
chronic morphine treatment. In addition, Ritzman et al. 
(1982) found that cyclo (Leu-Gly), when injected into rats 
prior to chronic exposure to morphine, inhibited 
morphine-induced increases in behavioral responses to 
dopamine agonists in addition to the inhibition of some signs 
of physical dependence.
Further studies were done to determine PLG binding sites 
in human brain. It was found that [3H] PLG bound to membrane 
homogenates with high affinity in a saturable manner. 
Substantia nigra had the highest level of specific [3H] PLG 
binding followed by striatum and hypothalamus. It was
concluded that specific PLG binding sites do exist in the
human brain and these binding sites may be strategically
localized to be able to modulate the changes in the number of
dopamine receptors (Chiu et al., 1980). It has also been
found that PLG has distinct binding sites in the rat brain,
with the highest density in substantia nigra and striatum.
PLG also selectively increases the affinity of the specific
*
binding of the dopamine agonist [3H] apomorphine to dopamine 
receptors and does not compete for dopamine/neuroleptic 
receptor binding (Chiu et al., 1981).
It can be concluded that PLG is a neuropeptide that 
interacts with specific binding sites in the brain and 
carries out specific functions related to modifying the 
dopamine system; the mechanism is not yet clear.
Katlonale:
This study was undertaken to determine whether postnatal 
challenge of rat pups with specific dopamine and D2 
receptor antagonists would modify the ontogeny of the 
respective receptor populations in the striatum and to 
determine whether PLG was capable of modulating the changes 
in the ontogeny of these dopamine receptors.
It would appear that chronic blockade of dopamine 
receptors may serve as a model by which many neurological and 
behavioral dysfunctions can be observed. For example, 
schizophrenia is conventionally treated with dopamine d2 
antagonists. However, protracted treatment with these agents
may lead to tardive dyskenesia in humans and to dopamine D2 
supersensitivity (increase in number) in rats (Chiu, 1981); 
prolonged treatment of Parkinson's Disease with dopamine 
agonists leads to dopamine receptor desensitization and 
worsens the disease manifestations (Rinne et al., 1979). 
Dopamine desensitization mimics down-regulation of dopamine 
receptors (decrease in number). In rats, dopamine receptor 
down-regulation may be caused by prenatal treatment with 
dopamine D2 antagonists (Rosengarten and Friedhoff, 1979}. 
Acute and chronic cocaine administration in rats causes 
dopamine receptor supersensitivity (Taylor et al., 1979), 
which may be the reason behind severe cravings for cocaine 
and the resulting abuse of cocaine in humans (Dackis and 
Harks, 1984). A better understanding of these processes could 
be of value in promoting the development of a viable 
treatment for these types of dysfunctions in man. For 
example, PLG may be of use in antagonizing the dependence and 
dysfunctions caused by drugs of abuse. PLG may also be of 
benefit in combination with anti-psychotic drugs, in order to 
prevent the development of tardive dyskinesia. Similar uses 
of PLG are suggested for preventing L-dopa-induced side 
effects in Parkinsonian patients.
In summary, the present study was undertaken to study 
dopamine receptor ontogeny under chronic blockade with 
specific antagonists and to test the ability of PLG to 
attenuate any abnormal changes in that ontogeny.
chapter II 
Material and Method
J
This project can be divided into two experiments. The 
first experiment was conducted to determine the effect of 
chronic blockade with specific antagonists on the ontogeny of 
dopamine and D2 receptors and to test the ability of plg 
to attenuate receptor changes produced by the antagonists.
The second experiment can be divided into two studies: 
The first study was undertaken to test the long-term effect 
of specific neonatal blockade on dopamine and D2 
receptors. Rats were treated with specific dopamine or D2 
antagonists for 32 days, then studied at 12 weeks. The 
second study was undertaken to determine adult dopamine 
and D2 receptor response to specific blockade; 12 week old 
rats were treated with specific antagonists for 17 days, then 
decapitated. The same rats had been treated postnatally for 
32 days from the day of birth.
Animals and Treatment:
Timed pregnant Sprague Dawley albino rats were obtained 
from Charles River Labs (Reserach Triangle, NC). Animals 
were housed individually in plastic cages and maintained 
under standard laboratory conditions (ad libitum access to 
food and water, temperature of 22±1 °C, and 12 hour 
light-dark cycle, on at 0700 hour). Starting at birth, all 
neonates were treated once a day for 32 successive days by
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intraperitoneal injection (i.p.) with one of the following 
regimens: (a) saline (0.9%), the SCH-23390.HC1 solvent, plus
saline containing tartaric acid (0.5%), the spiroperidol 
solvent, and acetic acid (0.5 mM), the PLG solvent, (b) 
SCH-23390.HCl (0.30 mg/kg, free base; Research Biochemicals, 
Inc., Natick, HA) in saline (0.9%) plus saline-tartaric 
acid/acetic acid, (c) spiroperidol (1.0 mg/kg i.p., Research
V
Biochemicals) in saline-tartaric acid/acetic acid plus 
saline, (d) SCH-23390 plus spiroperidol, (e) PLG (1.0 mg/kg) 
in saline-acetic acid, (f) PLG + SCH-23390,(g)PLG+ 
spiroperidol, or (h) PLG + SCH-23390 + spiroperidol. Rats 
were weaned at 4 weeks and decapitated at 5, 8, or 12 weeks 
of age. At 12 weeks of age, groups of animals were treated 
again, once a day for 17 consecutive days. Rats that had 
been treated neonatally with saline plus saline-tartaric 
acid/acetic acid or with SCH-23390, or with spiroperidol or 
with the combination of SCH-23390 plus spiroperidol received 
the identical treatment at 12 weeks of age. For rats treated 
as adults, an interval of three days elapsed between the last 
treatment and the time of decapitation to allow time for 
elimination of drugs from striatal tissue. After 
decapitation, brains were immediately removed and the striata 
were dissected free, frozen on dry ice, and stored at-60° c. 
Tissue Preparation:
At the time of assay striata were placed in 30 volumes 
of 50 mM Tris buffer (pH 7.4) containing 120 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 10 uM pargyline, 0.1% ascorbic acid and 1 uM
ketanserin, the serotonin S2 receptor antagonist (Janssen
Pharmaceutical Co., Beerse, Belgium). After homogenization
(setting of 50, 20 s; Tekmar Tissumizer) tissue suspensions
were incubated at 37° C for 30 minutes, in order to allow
dissociaton of any drug residue from the tissue. Samples were
centrifuged at 4B,OOOg for 25 min at 10° C in a Beckman
*
L5-75B ultracentrifuge. This step was repeated after 
resuspending the pellets in 30 volumes of fresh buffer. The
final pellets were resuspended in the Tris-salt solution.
Binding Assay;
To assess total dopamine receptor binding, the method 
of Schulz et al. (1985) was employed. Briefly, samples of
0.2 ml of homogenate were added to [3H]SCH-23390 (300 pM, 
final conc.; Amersham) in Tris-salt solution containing 2 mM 
CaCl2. Samples (l ml incubation mix) were incubated for 15
min at 37° C in a shaking water bath, and then rapidly 
filtered under partial vacuum on Whatman GF/F glass fiber 
filters using a Millipore filtration unit. Filters were 
washed three times with ice-cold Tris-salt solution. After 
drying, filters were placed in 10 ml of Scintiverse E (Fisher 
Scientific), and tritium activity was determined in a Beckman 
LS 9800 liquid scintillation spectrometer. Specific binding 
of [3H] SCH-23390 was defined as the difference in binding in 
the presence and absence of SCH-23390 (1 uM).
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D5 Binding Assay:
To assess total dopamine D2 receptor binding the method 
of Creese and Snyder (1979) was used. Aliquots of homogenate 
(0,2 ml) were incubated with [3H] spiroperidol (300 pM, final 
conc.; Amersham) in Tris-salt solution (1 ml incubation mix) 
for 15 min at 37° C, and then rapidly filtered on Whatman 
GF/F glass fiber filters. Specific binding of [3H] 
spiroperidol represented the difference in binding in the 
presence and absence of d-butaclamol (1 uM; Research 
Biochemicals, Inc.).
Kinetics Studies:
In order to determine the Bmax and Kp values for [3H] 
SCH-23390 and [3H] spiroperidol receptor binding, Scatchard 
analysis was used on the binding data from striatal 
homogenates of 5 week old rats.
For [3H] SCH-23390 kinetic studies in rat striata, which 
reflect dopamine binding, rats were treated for 32 days 
from day of birth with (a) saline, (b) SCH-23390 (0.3 mg/kg 
i.p), (c) PLG (1.0 mg/kg or (d) SCH-23390 + PLG. The [3H] 
SCH-23390 concentrations ranged from 50 to 1500 pM (8 
concentrations, total). For [3H] spiroperidol kinetic studies 
in rat striata, which reflect dopamine D2 binding, rats were 
treated for 32 days from day of birth with (a) saline, (b) 
spiroperiodol (1.0 mg/kg i.p), (c) PLG (1.0 mg/kg i.p), or 
(d) spiroperidol + PIX3. The [3H] Spiroperidol concentrations 
ranged from 50 to 1500 pM (8 concentrations, total).
Data Analysis
In the developmental study an analysis of variance 
(ANOVA) followed by a post-ANOVA Newman-Keuls test was used 
to analyze the data and to test for significant differences 
between the treatment groups. To test for the ability of 
receptor antagonists to produce an upregulation of dopamine 
Dj and D2 receptors an ANOVA was also used. A p value of 
<0.05 was considered to be the level for statistical 
significance.
Chapter III 
Results
1. Ontogenic Impairment of striatal Receptors by Neonatal 
SCH-23390!
Administration of the dopamine receptor antagonist, 
SCH-23390 (0.30 mg/kg, i.p.) to rats, once a day for 32 
successive days from birth, resulted in a marked impairment 
of striatal dopamine Di receptors at 5, 8 and 12 weeks 
(p<0.001) (figs. 1, 2, and 3). In the group of rats treated 
chronically with SCH-23390, total in vitro binding of 
[^H]SCH-23390 to striatal homogenates was reduced by about 
75% at all time intervals. Groups treated with the 
combination of SCH-23390 and spiroperidol (1 mg/kg i.p.) 
exhibited the same degree of impairment of dopamine D]_ 
receptors binding as those treated with SCH-23390 alone, 
indicating that dopamine D2 receptor antagonism in 
development does not permanently modify the ontogenic 
impairment of dopamine receptors by SCH-23390. Also, 
chronic spiroperidol treatment alone during ontogeny did not 
alter the development of striatal dopamine receptors, as 
assessed at 8 and 12 weeks (figs. 2 and 3). However, 
spiroperidol altered dopamine receptor by 20% at 5 weeks 
(fig. 1).
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Figure l. Total [3H]SCH-23390 binding to striatal 
homogenates of 5 week old rats, chronically treated 
postnatally with SCH-23390 and/or spiroperidol. Animals were 
treated i.p. once each day for 32 consecutive days from birth 
with saline, spiroperidol (1.0 mg/kg), SCH-23390 (0.30 
mg/Kg), or spiroperidol plus SCH-23390.
Each column represents the mean (+ S.E.H.) specific binding 
of [3H]SCH“23390 (300 pM; pmol/g tissue), Values represent 
data from 4 animals per group.
+, significantly different from the saline control group, 
p<0.05; *, p <0.001, compared to the saline control group.
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Figure 2. Total [3H]SCH-23390 binding to striatal 
homogenates of 8 week old rats, chronically treated 
postnatally with SCH-23390 and/or spiroperidol. Animals were 
treated i.p. once each day for 32 consecutive days from birth 
with saline, spiroperidol {1.0 mg/kg), SCH-23390 (0.30 
mg/kg), or spiroperidol plus SCH-23390. Each column 
represents mean (+ S.E.M.) specific binding of [3H]SCH-23390 
(300 pM; pmol/g tissue) to striatal homogenates derived from 
rats at 8 weeks from birth.
*,Statistically different from the saline control group
( p  < 0 . 0 0 1 ) .
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Figure 3. Total [3H]SCH-23390 binding to striatal 
homogenates of 12 week old rats, chronically treated 
postnatally with SCH-23390 and/or spiroperidol. Animals were 
treated i.p. once each day for 32 consecutive days from birth 
with saline, spiroperidol (1.0 mg/kg), SCH-23390 (0.30 
mg/kg), or spiroperidol plus SCH-23390. Each column 
represents mean (+ S.E.M.) specific binding of [3H]SCH-23390 
(300 pM; pmol/g tissue).
Control group represents [3H] SCH-23390 binding of
12.5 ±0.8 pmol/g tissue.Values represent data from 4 animals
per group.
*, statistically different from the saline control group
( p  < 0 . 0 0 1 ) .
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2. Ontocrenlc Impairment of Striatal Dopamine P2 Receptors bv 
Neonatal Spiroperidol:
When the dopamine D2 receptor antagonist, spiroperidol
(1.0 mg/kg i.p.), was administered to rats once daily for 32
consecutive days from birth, there was a marked impairment of
the development of striatal dopamine D2 receptors at 5, 8 and
12 weeks (p<0.001) (figs. 4,5 and 6). Chronic spiroperidol
*
alone reduced total [3H] spiroperidol binding to striatal 
membranes by 74%, 51% and 70%, at 5, 8, and 12 weeks, 
respectively. This effect was not modified in the group of 
rats treated with spiroperidol and SCH-23390, indicating that 
dopamine D2 receptor antagonism during development does not 
modify the ontogenic impairment of dopamine D2 receptors by 
spiroperidol. Similarly, chronic SCH-23390 treatment alone 
during ontogeny did not alter the development of striatal 
dopamine D2 receptors at 8 weeks. However, SCH-23390 altered 
dopamine D2 receptors by 20% at 5 weeks (fig. 4).
3. Dopamine Receptor Kinetic Studies:
Dopamine receptor kinetic studies were performed on 
striatal tissue from 5 week old rats treated chronically with 
saline, SCH-23390, PLG, and SCH-23390 + PLG, respectively. It 
was found that treatments with SCH-23390 and/or PLG did not 
alter the from the control (K^ of saline group, 348.6+9.1 
pM; mean and S.E.M).
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Figure 4. Total [3H]spiroperidol binding to striatal 
homogenates of 5 week old rats, chronically treated with 
spiroperidol and/or spiroperidol + SCH-23390. Animals were 
treated i.p. each day for 32 consecutive days with saline, 
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or 
spiroperidol plus SCH-23390. Each column represents mean 
(+S.E.M.) specific binding of [3H]spiroperidol (300 pM; 
pmol/g tissue).
Values represent data from 4 animals per group.
+, significantly different from the saline control group, 
p <0.05;
*, p <0.001, compared to the saline control group.
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Figure 5. Total [3H]spiroperidol binding to striatal 
homogenates of 8 week old rats, chronically treated with 
spiroperidol and/or spiroperidol + SCH-23390. Animals were 
treated i.p. each day for 32 consecutive days with saline, 
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or 
spiroperiodol plus SCH-23390. Each column represents the mean 
(+ S.E.M.) specific binding of [3H] spiroperidol (300 pM; 
pmol/g tissue}. Values represent data from 4 animals per 
group.
*, p <0.001, compared to the saline group.
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Figure 6. Total [3H]spiroperidol binding to striatal 
homogenates of 12 week old rats, chronically treated with 
spiroperidol and/or spiroperidol + SCH-23390. Animals were 
treated i.p. each day for 32 consecutive days with saline, 
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or 
spiroperidol plus SCH-23390. Each column represents the mean 
(+ s.E.M.) specific binding of [3H] spiroperidol (300 pH; 
pmol/g tissue).
Control group represents [3H] spiroperidol binding of 19+0.8 
pmol/g tissue.
Values represent data from 4 animals per group.
*, p <0.001, compared to the saline control group.
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However, SCH-23390 treatment effectively reduced the Bmax by 
78% from control (Bmax of saline group, 55.0+0.6 fmo1/mg 
tissue) as shown in table 1 and figure 7*
4. Dopamine Do Receptor Kinetic Studies:
Dopamine D% receptor kinetic studies were performed on 5 
week old rats treated chronically with saline, spiroperidol, 
PLG, and spiroperidol + PLG, respectively. It was found that
m
treatments with spiroperidol and/or PLG did not alter the KD 
from the control (Kj) of saline group, 168+4.3 pM; mean and
5.E.M.). However, spiroperidol treatment effetively reduced 
the Bmax by 75% from control (Bmax of saline group, 24.6+0.8 
fmol/mg tissue) as shown in table 2 and figure 8.
5. PLG Attenuation of Receptor Impairment:
In groups of rats that were co-treated with the 
neuropeptide PLG (1 mg/kg ip., for 32 days from day of 
birth), there was complete attenuation of the effects of 
chronic treatments with the dopamine D^ and D2 receptor 
antagonists*
In rats decapitated at 5 weeks (table 1) and at 8 weeks 
(fig. 2), the total in vitro binding of dopamine D^ receptors 
was similar in the saline control and PLG + SCH-23390-treated 
groups. These results demonstrate the ability of PLG to 
prevent the ontogenically impaired development of dopamine D^ 
receptors by chronic postnatal SCH-23390 treatment. Also, PLG 
treatment for 32 days from birth, along with spiroperidol 
(1 mg/kg i.p.), resulted in normal complement of striatal
29
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Figure 7. Scatchard analysis derived from [3H]SCH-23390 
binding data of striatum of 5 week old rats. Each treatment 
group represents the mean binding of 3 animals treated for 
32 days postnatally with saline (i\), PLG , l mg/kg) , SCH 
( ■  0.3 mg/kg), or PLG + SCH-23390 ( Q  , 1 mg/kg).
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Table 1.
Effect of 32 day postnatal treatments on rat striatal 
dopamine D1 receptors+ , as determined by Scatchard analysis 
of [H] SCH-23390 binding data.
Treatment Bmax 
(fmol/mg tissue)
k d
(pM)
Saline 54.9 ±  0.6 348.6 + 9.1
PLG (1.0 rag/kg/d) 56.6 + 2.2 334.0 4* 4.8
SCH-23390 (0.30 mg/kg/d) 12.3 ± 0.6* 328.0 + 5.3
PLG + SCH-23390 54.5 ± 1.8 339.0 + 3.8
+ Each value is the + S.E.M. of 3 tissues.
* Indicates a significant difference from the saline control 
group, p <0.001.
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Fig. B. Scatchard analysis derived from [3H] spiroperidol 
binding data of striatum of 5 week old rats. Each treatment 
groups represent the mean binding of 3 animals treated for 32 
days postnatally with saline (A), PLG ^  , 1 mg/kg), 
spiroperidol ,1 mg/kg), or PLG + spiroperidol ,
1 mg/kg).
Table 2. 32
Effect of 32 day postnatal treatments on rat striatal 
dopamine D2 receptor*, as determined by Scatchard analysis of 
[3H] spiroperidol binding data.
Treatment Bmax 
(fmol/mg tissue)
k d
(pM)
Saline 24.6 ± 0.8 168.0 + 4.3
PLG (1.0 mg/kg/d) 23.9 + 0.4 159.0 ± 4.9
Spiroperidol (1.0 mg/kg/d) 6.3 ± 0.2* 181.7 ± 3.2
PLG + Spiroperidol 23.6 + 0.6 162.0 + 4.5
+ Each value is the mean + S.E.M. of 3 tissues.
* Indicates a significant difference from the saline control 
group, p <0.001.
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dopamine D2 receptors at 5 weeks (table 2) and at 8 weeks 
(fig. 8). These results also demonstrate the ability of PLG 
to prevent the ontogenic impairment (decrease in number) of 
dopamine D2 receptors when chronically blocked with a 
specific antagonist (i.e. spiroperidol).
In conclusion, PLG is able to maintain a normal development 
of dopamine receptors when these receptors are challenged
9
with chronic specific antagonist treatment.
6. Up-Reaulation of Ontoaenlcallv Impaired Striatal Dopamine
Dj Receptors After Chronic SCH-23390 Challenge of Adult Rats;
In order to determine whether groups of rats with
ontogenically impaired striatal dopamine receptors could
respond to adult challenge with a dopamine receptor
antagonist by up-regulating receptors, rats at 12 weeks of
age were given SCH-23390 (0.30 mg/kg i.p.) once a day for 17
successive days. After a three day drug-free period, rats
were decapitated and total in vitro binding of [3H] SCH-23390
to striatal membranes was assessed. It was found that when
ontogenically impaired rats were treated for 17 days with 
» *
SCH-23390, an up-regulation of dopamine receptors 
(pco.ool) (fig. 9) resulted. In the group of rats treated 
during postnatal ontogeny with SCH-23390, total [3H]
SCH-23390 in vitro binding to striatal membranes was reduced 
by 74% at 12 weeks (fig. 3). However, when SCH-23390 was 
administered for 17 days in these mature rats, the result was 
a three-fold increase in [3H] SCH-23390 binding, to 75% of
saline control levels. When spiroperidol was administered 
alone (1.0 mg/kg i.p.), for 17 consecutive days in mature 
rats, an up-regulation of dopamine receptors did not 
result. Furthermore, when spiroperidol was administered in 
conjunction with SCH-23390 to 12 week old rats for 17 days, 
the response was the same as after treatment with SCH-23390 
alone. Thus, dopamine receptor antagonism in mature rats
V
results in an up-regulation of striatal dopamine Dj receptors 
even when this population of receptors is developmentally 
reduced in number. Challenge of these dopamine D]_ 
receptor-impaired adult rats with a dopamine D2 receptor 
antagonist did not modify receptor binding.
7. Lack of Up-Reoulatlon of Ontogenically Impaired Striatal 
Do Receptors After Chronic Spiroperidol Challenge of Adult 
Rats:
A 17 day treatment with spiroperidol (1.0 mg/kg/d i.p.) 
in 12 week old rats with ontogenically impaired development 
of striatal dopamine D2 receptors failed to change in vitro 
binding of [3H] spiroperidol to striatal membranes at 12 
weeks (fig. 10). Also, when SCH-23390 was administered to 
mature rats, alone or in combination with spiroperidol, the 
binding of [3H] spiroderidol was not enhanced.
In groups of rats treated during postnatal ontogeny with 
spiroperidol, [3H] spiroperidol in vitro binding of dopamine 
Dj> receptors was reduced by 70% at 12 weeks (fig. 6) ,
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Figure 9. Total [■1H]SCII*‘23390 binding to striatal homogenate 
of 12 week old rats. Animals were chronically treated with 
SCH-23390 as neonates, and again as adults. Neonatal rats 
were treated once each day for 32 consecutive days from birth 
with diluent or SCH-23390 (0.30 mg/kg i.p.). At 12 weeks 
after birth the diluent group received an additional 17 daily 
treatments with diluent, while the SCH-23390 group received 
an additional 17 daily treatments with SCH-23390.
Each column represents the mean (+S.E.M.) specific binding of 
[3H] SCH-23390 (300pM? pmol/g tissue).
Control group represents [3H] SCH-23390 binding of 1 4 + 0 . 3  
pmol/g tissue.
*, p <0.001, compared to the saline control group.
+, p <0.001, compared to the saline control group and SCH- 
23390-treated group.
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Fig. 10. Total [3H]spiroperiodol binding to striatal 
homogenates of 12 week old rats. Animals were chronically 
treated with spiroperidol as neonates and again as adults. 
Neonatal rats were treated once each day for 32 consecutive 
days from birth with diluent or spiroperidol (1.0 mg/kg 
i.p.). At 12 weeks after birth, the diluent group received 
an additional 17 daily treatments with diluent, while the 
spiroperidol group received an additional 17 daily treatments 
with spiroperidol (1.0 mg/kg i.p.). Each column represents 
the mean (+S.E.M.)- specific binding of [3H] spiroperidol (300 
pM; pmol/g tissue).
Control group represents [3H] spiroperidol binding of 
13 + 0.26 pmol/g tissue.
*, p <0.001, compared to the saline control group.
Chapter IV 
Discussion
1. Ontogenic Impairment of Dopamine and Do Receptors:
The present study has shown that chronic postnatal 
treatment of rats with highly selective dopamine or D2 
antagonists results in a persistent impairment of striatal 
dopamine and D2 receptor ontogeny, respectively, as 
measured at 5, 8, and 12 weeks by total in vitro binding 
assays. At 5 weeks only, SCH-23390-treatment resulted in a 
20% decrease in total [3H] spiroperidol binding to striatum, 
while spiroperidol treatment resulted in a 20% decrease in 
total [3H] SCH-23390 binding. This finding demonstrates that 
the postnatal period is sensitive and critical for normal 
development of striatal dopamine Dj_ and D2 receptors, and 
that the chronic blockade of dopamine receptors during this 
period may lead to permanent impairment in the ontogeny of 
the receptors.
The impairment in dopamine receptor ontogeny is 
reflected by the decrease in the total specific binding 
measured by in vitro assays or, simply a decrease in the 
number of dopamine receptors. At the time that dopamine D2 
receptors are ontogenically impaired, the dopamine 
receptor binding is normal and vice versa. This suggests a 
functional impairment in the dopamine system, not an 
anatomical one. In rat striatum there is evidence that
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dopaminergic innervation is incomplete at the time of
maturation of striatal dopamine D2 receptors, receptors,
and dopamine-stimulated adenylate cyclase (Giorgi et al.,
1987; Pardo et. al., 1977). The density of the dopamine Di
receptors increased rapidly from 9% of the adult level at
birth, to a peak value by postnatal day 35 (Giorgi et al.,
1987). The dopamine content at birth is 12% of the adult
level and increase slowly until reaching adult level by
postnatal day 60. The dopamine content is an indication of
dopaminergic innervation and presynaptic terminal maturation.
Therefore, it can be suggested that the postnatal period is a
critical period with regard to dopaminergic development, and
antagonistic treatment during this period may alter this
development, mainly through postsynaptic receptor sites. The
impairment in dopamine receptor ontogeny is apparently due to
impairment in the ability of the dopamine receptor cells to
express a normal number of dopamine receptors after chronic
blockade. Also, specific chronic blockade of dopamine
receptors may interfere with signals that are transmitted to 
*
the cell nuclei to stimulate greater expression of dopamine 
receptors (up-regulation). An increase in the number of 
striatal O2 receptors was observed when haloperidol was 
administered to rats for the first three weeks from birth 
(Kosengarten and Friedhoff, 1979) or when adult rats were 
chronically treated with haloperidol (Chiu et al., 1981).
The same up-regulatory response was observed when dopamine
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receptors were chronically blocked by SCH-23390 in adult rats 
(Creese and Chen, 1985),
In the prenatal study by Rosengarten and Friedhoff 
(1979) dopamine D2 ontogeny was permanently impaired 
following haloperidol treatment during a 3-day critical 
period (15-18 days of gestation). In their postnatal study 
dopamine D2 receptor up-regulation was reported following 
haloperidol treatment for 3 weeks from birth. There are 
several differences between the present study and the earlier 
postnatal study.
In the earlier study, the amount of haloperidol received 
by each pup in the milk could not be easily quantified, and 
as the pups approached 21 days of age, any consumption of 
pelleted food may have reduced milk and drug consumption.
Also, haloperidol may have affected the hormonal system in 
the lactating dams, by blocking D2 receptors in the pituitary 
gland, which increases prolactin release and may further 
dilute the drug in the milk. In the earlier report, 
serotonin S2 receptors were not inactivated in the in vitro 
procedure for [3H] spiroperidol binding, so that serotonin S2 
receptor changes may have artifactually altered results.
This does not exclude the possibility of serotonin S2 sites 
proliferating as a result of haloperidol treatment, which 
would make the binding assay results non-specific for 
dopamine D2 receptors. In the present study, spiroperidol, a 
more specific dopamine D2 receptor antagonist was used, with
the dose kept constant during the treatment period. Xn 
addition, ketanserin, a serotonin S2 receptor antagonist 
(Leyson et al., 1981) was employed in the in vitro binding 
assay. Also, in this study neonates were treated daily for 
32 days, not only for 21 days; the period between 21 and 32 
days could be critical for the development of dopamine 
receptors. It is suggested that the continuous treatment for 
32 days may be needed in order to accumulate enough changes 
that persistent impairment in dopamine receptor ontogeny can 
be observed.
Regarding the ability of dopamine D2 antagonists to
alter dopamine receptor ontogeny by 20% at 5 weeks, it can
be suggested that the chronic blockade of dopamine D2
receptors in the postnatal period is able to impair normal
expression of dopamine receptors. However, this
impairment is transient, and dopamine receptors regain
development to normal levels after treatment with dopamine D2
antagonists is terminated. The same reasoning may be applied
to the way dopamine antagonists affect dopamine D2 
*
receptors.
In conclusion, the present findings demonstrate that the 
process of striatal dopamine and D2 receptor development 
can be substantially impaired by chronic antagonist treatment 
in the postnatal period. It is not known at this time 
whether there is a specific period during postnatal 
development when the receptors are particularly susceptible
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to antagonists. Additional studies are needed to define the 
mechanisms that are associated with the altered ontogeny of 
dopamine receptors.
2. PLG Attenuation of Dopamine Receptor Ontooenic 
Impairment;
The ability of PLG to attenuate dopamine and D2 
ontogenic impairment is a new finding. It has been reported 
that PLG modulates the neuroleptic-induced up-regulation of 
dopamine D2 receptors in adult rats (Chiu et al., 1981; 
Bhargava, 1984). However, this neuroleptic-induced receptor 
up-regulation is a relatively short-lived phenomenon, since 
within 2 weeks after the termination of treatment, dopamine 
receptor number is at control levels. In the present study, a 
down-regulation of dopamine D2 receptors was effected. This 
change persisted for at least 3 to 4 months, and the reversal 
or prevention of this persistent change in dopamine D2 
receptor number by PLG is of great importance regarding 
possible regulatory mechanisms associated with receptor 
development. It is also of great importance regarding their 
ontogenic impairment during neurological dysfunction related 
to the dopamine system.
In addition, the present study demonstrates that PLG is 
able to attenuate the persistent ontogenic impairment of 
striatal dopamine receptors after chronic treatment with 
SCH-23390. These results highlight the involvement of PLG in
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modulating dopamine and dopamine D2 receptor development 
and ontogenic impairment.
It has been reported that, when added in combination 
with apomorphine, PLG acutely lowers the Kq (an increase in 
the affinity of the receptor to bind to the agonist) for 
in vitro binding of [3H] apomorphine to striatal homogenates 
without affecting [3H] spiroperidol binding (Bhargava, 1983 & 
1984; Chiu et al., 1981). It is therefore suggested that PLG 
may act in vitro to potentiate dopaminergic neurotransmission 
by interacting with its own binding sites, which are located 
in an area that allows them to influence dopamine receptor 
activity. It is also suggested that PLG is able to alter 
neuronal gene expression and the de novo synthesis of new 
dopamine receptor protein, since the short half-life of PLG 
will not allow it to act on or compete for the dopamine 
receptor sites and to have such a strong ability to modulate 
dopamine receptor ontogeny. PLG may act directly on the gene 
that expresses dopamine receptors, in order to modulate any 
abnormal changes in that expression. It should also be 
mentioned that dopamine neuronal activities are modulated by 
the action of neurochemical systems (i.e. GABA, substance P, 
enkephalin) (Kelley et al., 1982), and a reduction in these 
neurochemicals may lead to a profound motor behavior 
dysfunction, i.e. Huntington's Disease (Emson et al., 1980). 
The possibility needs to be considered that PLG may be 
indirectly modulating dopamine receptors through an action on
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these other neurochemical systems. It may he useful to 
determine the action of chronic PLG treatment on the above 
substances, under long-term blockade with dopamine and D2 
antagonists.
The present results demonstrate that the neuropeptide 
PLG is able to attenuate the impaired ontogenic development 
of striatal dopamine and D2 receptors that is produced by 
specific receptor antagonists. Explanation of this 
phenomenon should lead to a better understanding of dopamine 
receptor regulation and related neuroreceptor dynamics.
These results reinforce the previous suggestion (Chiu et al., 
1980, 1981) for the clinical use of PLG to attenuate abnormal 
dopamine receptor changes i.e. in Parkinson's disease, 
anti-psychotic therapy, and drug addiction.
3. The Ability of Dopamine Receptors to Up-Reaulate in 
Adults;
The present study has shown that the postnatal treatment 
of rats for 32 days from birth with the dopamine or D2 
receptor antagonists results in persistent ontogenic 
impairment of both and D2 dopamine receptors at 5, 8, and 
12 weeks of age. The study has also shown that dopamine D2 
receptors do not up-regulate (increase in number) when 
rechallenged in adult rats (fig. 8), On the other hand, 
dopamine receptors do up-regulate when rechallenged in 
adult rats (fig. 7).
This up-regulation of ontogenically impaired striatal
dopamine receptors after chronic treatment of adult rats 
with sCH-23390 is analogous to the up-regulation of 
unimpaired striatal dopamine Di receptors after SCH-23390 
treatment of adult rats (Creese and Chen, 1985). SCH-23390
chronic administration had no affect on striatal dopamine D2 
receptors in either the ontogenically impaired or control 
rats.
r
Failure of ontogenically impaired striatal dopamine D2 
receptors to up-regulate in response to challenge of adult 
rats with spiroperidol contrasts with the up-regulation of 
these receptors in intact control rats challenged as adults 
with neuroleptics (Seeman, 1980). It is possible that a 
higher dose of spiroperidol can stimulate dopamine D2 
up-regulation; however, the challenge doses of receptor 
antagonists are moderate and identical to the dose of 
antagonist that was administered during development. Also, 
in this study, both dopamine and D2 receptor binding was 
ontogenically impaired to the same degree, prior to adult 
challenge with a receptor antagonist. The differential 
up-regulation of dopamine receptors may reflect 
differences in the ability of the dopamine and D2 
receptors to respond to receptor antagonism. The adenylate 
cyclase system that is directly stimulated by dopamine 
receptors (Kababian and Caine, 1979) may have the ability to 
recover some of the normal response of dopamine D]_ receptors 
(up-regulation) upon challenging treatment. On the other
hand there is either no relationship or a negative 
relationship between dopamine D£ receptors and the adenylate 
cyclase system,* dopamine D2 receptors did not up-regulate. 
Also there is evidence that dopamine D2 receptors are 
modulated by the guanine nucleotide system (Grigoriadis and 
Seeman, 1985), which may have a different response to 
challenging treatment from that of the adenylate cyclase 
system regarding impaired striatal dopamine receptors.
In conclusion, ontogenically impaired dopamine and D2 
receptors showed different responses to challenging 
treatment, in which dopamine receptors up-regulated and 
dopamine D2 receptors did not, following treatment with 
specific antagonists as adults. This may be of importance 
with regards to the etiology and management of psychiatric 
disorders related to the dopaminergic system.
Chapter V 
Summary
Chronic postnatal treatment of rats with SCH-23390 or 
spiroperidol, selective dopamine D]_ or D2 receptor 
antagonists, causes permanent impairment in the development
V
of the respective striatal receptors. This developmental
impairment is reflected by a decrease in the specific binding
of [3H] SCH-23390 and [3H] spiroperidol, respectively, to
striatal homogenates as assessed at 5, 8 and 12 weeks. As
indicated at 5 weeks, the decrease in [3H] SCH-23390 and [3H]
spiroperidol binding is associated with a decrease in the
Bmax for the dopamine and D2 receptors, respectively.
Since the Kq is unchanged, the ontogenic impairment is
reflective of a change in number, not the affinity of the
dopamine and D2 receptor types. These results indicate
that the postnatal period is a sensitive and critical one for
normal expression of striatal dopamine receptors. The 
* *
neuropeptide PLG was able to totally attenuate the ontogenic 
impairment of striatal dopamine and D2 receptors that was 
caused by chronic postnatal treatment with selective dopamine 
and D2 antagonists. These results also indicate that PLG 
is capable of modulating abnormal developmental changes in 
striatal dopamine and D2 receptors.
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